A lens-derived tripeptide bioregulator studied for eye health and age-related vision support.
Derived from crystalline lens proteins, Crystagen is a tripeptide bioregulator proposed to target ocular tissue gene regulation. Research from Khavinson's group suggests it normalises crystallin expression in lens epithelial cells and may slow age-related protein aggregation that contributes to cataracts.
Part of the Khavinson peptide bioregulator system targeting eye tissue. Used in Russian ophthalmology as a supportive treatment for age-related vision deterioration and early cataract changes.
As with other bioregulators in this family, Crystagen is used in 10-day intramuscular or subcutaneous courses, repeated 2–4 times per year in longevity protocols.